Status:
UNKNOWN
Evaluation of Blood Platelet Indices,Platelet Aggregation in the Activity of IBD Patients on Biological Treatment
Lead Sponsor:
Assiut University
Conditions:
Bowel Disease
Inflammatory Bowel Diseases
Eligibility:
All Genders
21-65 years
Brief Summary
ulcerative colitis and Crohn's disease, the two major forms of inflammatory bowel disease, are chronic, idiopathic, relapsing inflammatory conditions of the gastrointestinal tract. The mechanism is mu...
Detailed Description
Histopathological examinations play a role in the diagnosis and management of UC, but they are costly and invasive. So, non-invasive inflammatory biomarkers of IBD, such as the WBCS, ESR and CRP are u...
Eligibility Criteria
Inclusion
- All patients diagnosed with inflammatory bowel disease ulcerative colitis or crohn's disease
- All IBD patients received biological treatment
- All IBD patients controlled with conventional treatment
Exclusion
- IBS patients
- IBD Patients with: a) another autoimmune disease like ITP and SLE B) Bleeding tendency as hemophilia or thrombophilia C) Previous thrombotic events or on anticoagulants or antiplatelet drugs D) With another comorbidity as liver cell failure, respiratory failure, renal failure and cardiac failure
Key Trial Info
Start Date :
June 5 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05406934
Start Date
June 5 2022
End Date
October 1 2024
Last Update
June 7 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.